Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

Respiratory Research

Gary T Ferguson¹  Donald P Tashkin² 

[1] Pulmonary Research Institute of Southeast Michigan, 28815 Eight Mile Road, Suite 103, Livonia, MI, 48152, USA;Department of Medicine, David Geffen School of Medicine at UCLA, 405 Hilgard Avenue, Los Angeles, CA, 90095, USA

关键词: Antimuscarinic;    Beta 2 agonist;    Bronchodilation;    Combination therapy;    COPD;   

Others  :  794704
DOI  :  10.1186/1465-9921-14-49

 received in 2013-01-28, accepted in 2013-04-24,  发布年份 2013

【 摘 要 】

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the classification of patients for treatment using a combination of spirometry, assessment of symptoms, and/or frequency of exacerbations. The aim of treatment remains to reduce existing symptoms while decreasing the risk of future adverse health events. Long-acting bronchodilators are the mainstay of therapy due to their proven efficacy. GOLD guidelines recommend combining long-acting bronchodilators with differing mechanisms of action if the control of COPD is insufficient with monotherapy, and recent years have seen growing interest in the additional benefits that combination of long-acting muscarinic antagonists (LAMAs), typified by tiotropium, with long-acting β₂-agonists (LABAs), such as formoterol and salmeterol. Most studies have examined free combinations of currently available LAMAs and LABAs, broadly showing a benefit in terms of lung function and other patient-reported outcomes, although evidence is limited at present. Several once- or twice-daily fixed-dose LAMA/LABA combinations are under development, most involving newly developed monotherapy components. This review outlines the existing data for LAMA/LABA combinations in the treatment of COPD, summarizes the ongoing trials, and considers the evidence required to inform the role of LAMA/LABA combinations in treatment of this disease.

【 授权许可】

   
2013 Tashkin and Ferguson; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: World health statistics 2008. http://www.who.int/whosis/whostat/2008/en/index.html webcite
• [2]Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R: Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188-207.
• [3]National Institutes of Health, National Heart, Lung, and Blood Institute: Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. http://www.nhlbi.nih.gov/resources/docs/2012_ChartBook.pdf webcite
• [4]Cazzola M, Matera MG: Emerging inhaled bronchodilators: an update. Eur Respir J 2009, 34:757-769.
• [5]Cazzola M, Calzetta L, Matera MG: β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
• [6]Matera MG, Page CP, Cazzola M: Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011, 32:495-506.
• [7]Cazzola M, Page CP, Calzetta L, Matera MG: Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012, 64:450-504.
• [8]Cazzola M, Rogliani P, Segreti A, Matera MG: An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012, 21:1489-1501.
• [9]Global initiative for chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. http://www.goldcopd.org/guidelines-global-strategy-for-diagnisis-management.pdf webcite
• [10]US Food and Drug Administration: FDA approved drug products. Ipratropium. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm webcite]
• [11]Yohannes AM, Willgoss TG, Vestbo J: Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011, 56:477-487.
• [12]Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
• [13]Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G, on behalf of the Formoterol in Chronic Obstructive Pulmonary Disease I (FICOPD I) Study Group: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
• [14]Cazzola M, Santangelo G, Piccolo A, Salzillo A, Matera MG, D'Amato G, Rossi F: Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994, 7:103-107.
• [15]O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K: Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006, 130:647-656.
• [16]O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H: Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004, 23:832-840.
• [17]Aguilaniu B: Impact of bronchodilator therapy on exercise tolerance in COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:57-71.
• [18]Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr, for the US Tiotropium Study Group: The spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trial. Chest 2000, 118:1294-1302.
• [19]Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, Dolker M: Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010, 104:1482-1489.
• [20]Novartis Europharm Limited: SPC. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules. http://www.medicines.org.uk/EMC/medicine/23260/SPC/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder%2c+hard+capsules/ webcite
• [21]Novartis Pharmaceutical Corporation: ARCAPTA NEOHALER. Full prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s0002mg.pdf webcite
• [22]Moen MD: Indacaterol. In chronic obstructive pulmonary disease. Drugs 2010, 70:2269-2280.
• [23]Kerwin EM, Meli J, Peckitt C, Lassen C, Kramer B, Filcek S: Efficacy and safety of indacaterol 75 g [sic] once daily in patients with moderate-to-severe COPD [abstract]. Am J Respir Crit Care Med 2011, 183:A1595.
• [24]van Noord JA, Korducki L, Hamilton A, Koker P: Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract A6183]. Am J Respir Crit Care Med 2009, 179:A6183.
• [25]Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B: Dose-related efficacy of vilanterol trifenatate (VI) in COPD [abstract P1227]. Eur Respir J 2010, 36(Suppl 54):217s.
• [26]Tashkin DP, Fabbri LM: Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010, 11:149. BioMed Central Full Text
• [27]Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Garcia Gil E: Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 2010, 7:331-336.
• [28]Gavaldà A, Miralpeix M, Ramos I, Otal R, Carreño C, Viñals M, Doménech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J: Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009, 331:740-751.
• [29]Kerwin E, D'Urzo A, Gelb A, Lakkis H, Garcia Gil E, Caracta C: Twice-daily aclidinium bromide in COPD patients: efficacy and safety results from ACCORD COPD I [abstract P1235]. Eur Respir J 2010, 36(Suppl 54):219s.
• [30]D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:156. BioMed Central Full Text
• [31]Orevillo C, St Rose E, Strom S, Fischer T, Golden M, Thomas M, Reisner C: Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract P3975]. Eur Respir J 2011, 38(Suppl 55):724s.
• [32]Bateman E, Feldman G, Kilbride S, Brooks J, Mehta R, Harris S, Maden C, Crater G: Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clin Respir J 2012, 6:248-257.
• [33]Donohue JF, Siler T, Kerwin EM, Williams J, Kianifard F, McBryan D: Efficacy and safety of indacaterol 75 μg once daily in patients with moderate-to-severe COPD: pooled analysis of two phase III trials [abstract A2258]. Am J Respir Crit Care Med 2012, 185:A2258.
• [34]Kerwin EM, Hebert J, Pedinoff A, Gallagher N, Martin C, Banerji D, Lu Y, Overend T: NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [abstract]. Am J Respir Crit Care Med 2012, 185:A2920.
• [35]Cazzola M, Tashkin DP: Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009, 6:404-415.
• [36]Cazzola M, Molimard M: The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
• [37]Bouyssou T, Schnapp A, Casarosa P, Pieper MP: Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract A4445]. Am J Respir Crit Care Med 2010, 181:A4445.
• [38]Bouyssou T, Casarosa P, Pieper M, Schnapp A, Gantner F: Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs [abstract 3451]. Eur Respir J 2011, 38(Suppl 55):613s.
• [39]Kume H, Imbe S, Iwanaga T, Tohda Y: Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle [abstract 4835]. 2012. [Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5]
• [40]COMBIVENT Inhalation Solution Study Group: Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997, 112:1514-1521.
• [41]COMBIVENT Inhalation Aerosol Study Group: In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 105:1411-1419.
• [42]Guleria R, Behera D, Jindal SK: Comparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trial. J Assoc Physicians India 1991, 39:680-682.
• [43]ZuWallack R, De Salvo MC, Kaelin T, Bateman ED, Park CS, Abrahams R, Fakih F, Sachs P, Pudi K, Zhao Y, Wood CC, on behalf of the Combivent Respimat® inhaler Study Group: Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDI. Respir Med 2010, 104:1179-1188.
• [44]Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr: The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115:966-971.
• [45]Campbell S: For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999, 159:156-160.
• [46]van der Molen T, Cazzola M: Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012, 21:101-108.
• [47]van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJG: Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
• [48]Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, Bishop G, Anthony J, Cowie R, Field S, Hirsch A, Hernandez P, Rivington R, Road J, Hoffstein V, Hodder R, Marciniuk D, McCormack D, Fox G, Cox G, Prins HB, Ford G, Bleskie D, Doucette S, Mayers I, Chapman K: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Ann Intern Med 2007, 146:545-555.
• [49]van Noord JA, Aumann J-L, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJG: Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26:214-222.
• [50]Mahler DA, D'Urzo A, Peckitt C, Lassen C, Kramer B, Filcek S: Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone [abstract]. Am J Respir Crit Care Med 2011, 183:A1591.
• [51]Maltais F, Beck E, Webster D, Maleki-Yazdi MR, Seibt J-V, Arnoux A, Hamilton A: Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]. Eur Respir J 2010, 36(Suppl 54):1014s.
• [52]Reisner C, St Rose E, Strom S, Fischer T, Golden M, Thomas M, Orevillo C: Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract P879]. Eur Respir J 2011, 38(Suppl 55):150s.
• [53]Reisner C, Fogarty C, Spangenthal S, Dunn L, Kerwin EM, Quinn D, Seale JP, Thomas M, St Rose E, Orevillo CJ: Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]. Am J Respir Crit Care Med 2011, 183:A6453.
• [54]Vogelmeier C, Kardos P, Harari S, Gans SJM, Stenglein S, Thirlwell J: Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102:1511-1520.
• [55]Tashkin DP, Pearle J, Iezzoni D, Varghese ST: Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009, 6:17-25.
• [56]Tashkin DP, Littner M, Andrews CP, Tomlinson L, Rinehart M, Denis-Mize K: Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008, 102:479-487.
• [57]Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T: Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD 2010, 7:418-427.
• [58]van Noord JA, Buhl R, LaForce C, Martin C, Jones F, Dolker M, Overend T: QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
• [59]van Noord JA, Aumann J-L, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJG: Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104:995-1004.
• [60]Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT: Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009, 103:516-524.
• [61]Beier J, van Noord J, Deans A, Brooks J, Maden C, Baggen S, Mehta R, Cahn A: Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients. Int J Chron Obstruct Pulmon Dis 2012, 7:153-164.
• [62]Reisner C, Fernandez C, Orevillo C, St Rose E, Kollar C: Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva® HandiHaler® and placebo in patients with COPD [abstract]. Am J Respir Crit Care Med 2012, 185:A2925.
• [63]Feldman G, Walker RR, Brooks J, Mehta R, Crater G: Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD [abstract A2938]. Am J Respir Crit Care Med 2012, 185:A2938.
• [64]Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Pivovarova A, Schmidt O, Bjermer L: Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD. 2012. [Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5. [abstract 2882]]
• [65]Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K: Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs 2009, 69:1205-1216.
• [66]Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D'Avelli S: Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008, 102:1701-1707.
• [67]Dahl R, Chapman K, Rudolf M, Mehta R, Kho P, Alagappan V, Berhane I, Chen H, Banerji D: QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: the ENLIGHTEN study [abstract 2896]. 2012. [Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5]
• [68]Bateman E, Ferguson GT, Barnes N, Gallagher N, Green Y, Horton R, Henley M, Banerji D: Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [abstract 2810]. 2012. [Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5]
• [69]Vogelmeier CF, Bateman ED, Pallante J, Alagappan VKT, D'Andrea P, Chen H, Banerji D: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Resp Med 2013, 1:51-60.
• [70]Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, Centanni S: The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther 2004, 17:35-39.
• [71]Cazzola M, Noschese P, Salzillo A, De Giglio C, D'Amato G, Matera MG: Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. Respir Med 2005, 99:524-528.
• [72]Di Marco F, Verga M, Santus P, Morelli N, Cazzola M, Centanni S: Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med 2006, 100:1925-1932.
• [73]Rabe KF, Timmer W, Sagkriotis A, Viel K: Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008, 134:255-262.
• [74]Wang J, Jin D, Zuo P, Wang T, Xu Y, Xiong W: Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2011, 16:350-358.
• [75]Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA: Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med 2010, 104:1288-1296.
• [76]Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, Di Marco F, Matera MG: The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004, 98:1214-1221.
• [77]European Medicines Agency: Guideline on the non-clinical development of fixed combinations of medicinal products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003976.pdf webcite
• [78]US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf webcite
• [79]Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ: The risks and benefits of indacaterol — the FDA's review. N Engl J Med 2011, 365:2247-2249.
• [80]Gavalda A, Vinyals M, Aubets J, Gras J: Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs [abstract 2116]. 2012. [Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5]
• [81]Agusti A, Hedner J, Marin JM, Barbé F, Cazzola M, Rennard S: Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011, 20:183-194.
• [82]Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS: Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011, 105:435-441.
• [83]Yawn BP, Colice GL, Hodder R: Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis 2012, 7:495-502.
• [84]Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, Douglas G, Muers M, Smith D, White J: Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001, 5:1-149.
• [85]Dalby R, Spallek M, Voshaar T: A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm 2004, 283:1-9.
• [86]Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK: Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem 2011, 3:1703-1718.
• [87]Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I: Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010, 26:2527-2533.
• [88]Chrystyn H, Niederlaender C: The Genuair® inhaler: a novel, multidose dry powder inhaler. Int J Clin Pract 2012, 66:309-317.
• [89]Larsen JS, Hahn M, Ekholm B, Wick KA: Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma 1994, 31:193-199.
• [90]Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM: The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994, 150:1256-1261.
• [91]Brand P, Hederer B, Austen G, Dewberry H, Meyer T: Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis 2008, 3:763-770.
• [92]Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008, 102:593-604.
• [93]Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H: Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalers. J Aerosol Med 2005, 18:273-282.
• [94]Geller DE: Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005, 50:1313-1321.
• [95]Wieshammer S, Dreyhaupt J: Dry powder inhalers: which factors determine the frequency of handling errors? Respiration 2008, 75:18-25.
• [96]Lareau SC, Yawn BP: Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:401-406.
• [97]Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M, on behalf of the Gruppo Educazionale Associazione Italiana Pnemologi Ospedalieri (AIPO): Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011, 105:930-938.
• [98]Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J: Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011, 14:486-496.
• [99]Kesten S, Jara M, Wentworth C, Lanes S: Pooled clinical trial analysis of tiotropium safety. Chest 2006, 130:1695-1703.
• [100]Jung KS, Park HY, Park SY, Kim SK, Kim Y-K, Shim J-J, Moon HS, Lee KH, Yoo J-H, Lee SD: Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012, 106:382-389.
• [101]Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA: Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res 2012, 13:15. BioMed Central Full Text
• [102]Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
• [103]Pasqua F, Biscione G, Crigna G, Auciello L, Cazzola M: Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med 2010, 104:412-417.
• [104]Short PM, Williamson PA, Elder DHJ, Lipworth SIW, Schembri S, Lipworth BJ: The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012, 141:81-86.
• [105]Karner C, Cates CJ: The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease (Review). Cochrane Database Syst Rev 2011, 9:CD009039.
• [106]Hughes AD, Jones LH: Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011, 3:1585-1605.
• [107]Steinfeld T, Hughes AD, Klein U, Smith JAM, Mammen M: THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011, 79:389-399.
• [108]Fernandes LB, Henry PJ, Goldie RG: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2007, 1:25-33.
• [109]IMS Health, LifeLink Solutions: IMS data 5/2011-4/2012. 2012.
• [110]Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MPMH, Beeh KM, Rabe KF, Fabbri LM, for the POET-COPD Investigators: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
• [111]Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S: Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005, 127:809-817.
• [112]Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, Kesten S, O'Donnell D: Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005, 128:1168-1178.